-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 28, Watson Bio released its financial report for the first quarter of 2022.
During the reporting period, the Yuxi Watson 13-valent pneumonia conjugate vaccine, a subsidiary of Watson, received batches of 2,085,700 doses, an increase of 26.
During the reporting period, the details of Watson's products in the registration and application stage are as follows:
In terms of international business, Yuxi Watson's 13-valent pneumonia conjugate vaccine has obtained the market license in Morocco and completed the registration in Morocco